Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours

S. Cresta, C. Sessa, C. V. Catapano, E. Gallerani, D. Passalacqua, A. Rinaldi, F. Bertoni, L. Viganò, M. Maur, G. Capri, E. Maccioni, D. Tosi, L. Gianni

Research output: Contribution to journalArticle

Abstract

Background: The combination of a proteasome inhibitor with a taxane has potential clinical synergism that prompted a clinical test. Patients and methods: The maximum tolerated dose (MTD) and recommended dose (RD) of intravenous (i.v.) Bortezomib (B) (days 1, 4, 8, 11) and i.v. Paclitaxel (PTX) (days 1, 8) every 3 weeks was evaluated in patients with advanced solid tumours. The RD was tested in patients with breast, ovarian and prostate cancer. At the RD, microarray analysis of transcriptional profiles was carried out before and after the first dosing in peripheral blood mononuclear cells (PBMC). Results: Thirty-one patients were enrolled and 22 were treated at the RD that corresponded to B 1.3 mg/m2 and PTX 100 mg/m2. The main toxicity was cumulative peripheral neuropathy (76% of patients; grade 3-4 in 9%) that required treatment discontinuation in six patients, followed by diarrhoea (55%) and fatigue (41%). Nine partial responses (30%) were observed (three breast cancer, four ovary, two prostate patients). Significant (p <0.05) and consistent changes (>70% of patients) in transcriptome were observed. Conclusions: The incidence of peripheral neuropathy and the anti-tumour activity comparable to that of single-agent PTX do not support further development of this regimen.

Original languageEnglish
Pages (from-to)1829-1834
Number of pages6
JournalEuropean Journal of Cancer
Volume44
Issue number13
DOIs
Publication statusPublished - Sep 2008

Fingerprint

Paclitaxel
Neoplasms
Peripheral Nervous System Diseases
Ovarian Neoplasms
Breast Neoplasms
Proteasome Inhibitors
Maximum Tolerated Dose
Bortezomib
Microarray Analysis
Transcriptome
Fatigue
Prostate
Diarrhea
Blood Cells
Prostatic Neoplasms
Incidence

Keywords

  • Bortezomib
  • Clinical study
  • Combination
  • Phase I
  • Proteasome inhibitor
  • Solid tumours
  • Taxane
  • Weekly paclitaxel

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this

Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours. / Cresta, S.; Sessa, C.; Catapano, C. V.; Gallerani, E.; Passalacqua, D.; Rinaldi, A.; Bertoni, F.; Viganò, L.; Maur, M.; Capri, G.; Maccioni, E.; Tosi, D.; Gianni, L.

In: European Journal of Cancer, Vol. 44, No. 13, 09.2008, p. 1829-1834.

Research output: Contribution to journalArticle

Cresta, S, Sessa, C, Catapano, CV, Gallerani, E, Passalacqua, D, Rinaldi, A, Bertoni, F, Viganò, L, Maur, M, Capri, G, Maccioni, E, Tosi, D & Gianni, L 2008, 'Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours', European Journal of Cancer, vol. 44, no. 13, pp. 1829-1834. https://doi.org/10.1016/j.ejca.2008.05.022
Cresta, S. ; Sessa, C. ; Catapano, C. V. ; Gallerani, E. ; Passalacqua, D. ; Rinaldi, A. ; Bertoni, F. ; Viganò, L. ; Maur, M. ; Capri, G. ; Maccioni, E. ; Tosi, D. ; Gianni, L. / Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours. In: European Journal of Cancer. 2008 ; Vol. 44, No. 13. pp. 1829-1834.
@article{2768774e8a8a446db1e6753737725c8a,
title = "Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours",
abstract = "Background: The combination of a proteasome inhibitor with a taxane has potential clinical synergism that prompted a clinical test. Patients and methods: The maximum tolerated dose (MTD) and recommended dose (RD) of intravenous (i.v.) Bortezomib (B) (days 1, 4, 8, 11) and i.v. Paclitaxel (PTX) (days 1, 8) every 3 weeks was evaluated in patients with advanced solid tumours. The RD was tested in patients with breast, ovarian and prostate cancer. At the RD, microarray analysis of transcriptional profiles was carried out before and after the first dosing in peripheral blood mononuclear cells (PBMC). Results: Thirty-one patients were enrolled and 22 were treated at the RD that corresponded to B 1.3 mg/m2 and PTX 100 mg/m2. The main toxicity was cumulative peripheral neuropathy (76{\%} of patients; grade 3-4 in 9{\%}) that required treatment discontinuation in six patients, followed by diarrhoea (55{\%}) and fatigue (41{\%}). Nine partial responses (30{\%}) were observed (three breast cancer, four ovary, two prostate patients). Significant (p <0.05) and consistent changes (>70{\%} of patients) in transcriptome were observed. Conclusions: The incidence of peripheral neuropathy and the anti-tumour activity comparable to that of single-agent PTX do not support further development of this regimen.",
keywords = "Bortezomib, Clinical study, Combination, Phase I, Proteasome inhibitor, Solid tumours, Taxane, Weekly paclitaxel",
author = "S. Cresta and C. Sessa and Catapano, {C. V.} and E. Gallerani and D. Passalacqua and A. Rinaldi and F. Bertoni and L. Vigan{\`o} and M. Maur and G. Capri and E. Maccioni and D. Tosi and L. Gianni",
year = "2008",
month = "9",
doi = "10.1016/j.ejca.2008.05.022",
language = "English",
volume = "44",
pages = "1829--1834",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Ltd",
number = "13",

}

TY - JOUR

T1 - Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours

AU - Cresta, S.

AU - Sessa, C.

AU - Catapano, C. V.

AU - Gallerani, E.

AU - Passalacqua, D.

AU - Rinaldi, A.

AU - Bertoni, F.

AU - Viganò, L.

AU - Maur, M.

AU - Capri, G.

AU - Maccioni, E.

AU - Tosi, D.

AU - Gianni, L.

PY - 2008/9

Y1 - 2008/9

N2 - Background: The combination of a proteasome inhibitor with a taxane has potential clinical synergism that prompted a clinical test. Patients and methods: The maximum tolerated dose (MTD) and recommended dose (RD) of intravenous (i.v.) Bortezomib (B) (days 1, 4, 8, 11) and i.v. Paclitaxel (PTX) (days 1, 8) every 3 weeks was evaluated in patients with advanced solid tumours. The RD was tested in patients with breast, ovarian and prostate cancer. At the RD, microarray analysis of transcriptional profiles was carried out before and after the first dosing in peripheral blood mononuclear cells (PBMC). Results: Thirty-one patients were enrolled and 22 were treated at the RD that corresponded to B 1.3 mg/m2 and PTX 100 mg/m2. The main toxicity was cumulative peripheral neuropathy (76% of patients; grade 3-4 in 9%) that required treatment discontinuation in six patients, followed by diarrhoea (55%) and fatigue (41%). Nine partial responses (30%) were observed (three breast cancer, four ovary, two prostate patients). Significant (p <0.05) and consistent changes (>70% of patients) in transcriptome were observed. Conclusions: The incidence of peripheral neuropathy and the anti-tumour activity comparable to that of single-agent PTX do not support further development of this regimen.

AB - Background: The combination of a proteasome inhibitor with a taxane has potential clinical synergism that prompted a clinical test. Patients and methods: The maximum tolerated dose (MTD) and recommended dose (RD) of intravenous (i.v.) Bortezomib (B) (days 1, 4, 8, 11) and i.v. Paclitaxel (PTX) (days 1, 8) every 3 weeks was evaluated in patients with advanced solid tumours. The RD was tested in patients with breast, ovarian and prostate cancer. At the RD, microarray analysis of transcriptional profiles was carried out before and after the first dosing in peripheral blood mononuclear cells (PBMC). Results: Thirty-one patients were enrolled and 22 were treated at the RD that corresponded to B 1.3 mg/m2 and PTX 100 mg/m2. The main toxicity was cumulative peripheral neuropathy (76% of patients; grade 3-4 in 9%) that required treatment discontinuation in six patients, followed by diarrhoea (55%) and fatigue (41%). Nine partial responses (30%) were observed (three breast cancer, four ovary, two prostate patients). Significant (p <0.05) and consistent changes (>70% of patients) in transcriptome were observed. Conclusions: The incidence of peripheral neuropathy and the anti-tumour activity comparable to that of single-agent PTX do not support further development of this regimen.

KW - Bortezomib

KW - Clinical study

KW - Combination

KW - Phase I

KW - Proteasome inhibitor

KW - Solid tumours

KW - Taxane

KW - Weekly paclitaxel

UR - http://www.scopus.com/inward/record.url?scp=49549114644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49549114644&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2008.05.022

DO - 10.1016/j.ejca.2008.05.022

M3 - Article

C2 - 18640031

AN - SCOPUS:49549114644

VL - 44

SP - 1829

EP - 1834

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 13

ER -